Surzebiclimab (BGB-A425) is a humanized IgG1-variant monoclonal antibody against T-cell immunoglobulin and mucin-domain containing-3 (TIM-3). Surzebiclimab binds to the extracellular domain of human Tim-3 with high affinity (KD=0.36 nM) and specificity. Surzebiclimab can be used in research of cancer.
Surzebiclimab (BGB-A425; 0.1-100 μg/mL) efficiently blocks the interactions between Tim-3 and PtdSer. Surzebiclimab enhances IFN-γ production of primary T cells and NK-mediated cytotoxicity against tumor cells[1].Surzebiclimab augments T-cell response to allogeneic antigens either alone or in combination with an anti-PD-1 antibody BGB-A317. Surzebiclimab can also induce the internalization of Tim-3 receptor on cell surface[1].
Surzebiclimab (BGB-A425) in combination with BGB-A317 inhibits tumor growth in a mouse xenograft cancer model[1].
References:
[1]. Tong Z, et, al. Abstract 2628: BGB-A425: a humanized anti-human Tim-3 antibody that exhibits strong immune cell activation. Cancer Res. 2017;77:(13_Supplement):2628.